GlassScriptPhysician profile
Noemi E Lozano
NPI 1356572903
$2,220.27
in general payments reported to CMS, 2019-2025
11 companies · $666 in 2025
The $666 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $86.30 · 2021: $251 · 2022: $305 · 2023: $144 · 2024: $589 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.97 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $554.35 | 2021-2025 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Biotissue Holdings INC. | $395.65 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $300.36 | 2019-2025 | |
| Alcon Vision LLC | $270.13 | 2021-2025 | Precision7, Total30, Precision 1 |
| Abbvie INC. | $194.61 | 2022-2024 | |
| Regeneron Pharmaceuticals, INC. | $130.02 | 2023 | Eylea |
| Astellas Pharma US INC | $115.06 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $86.30 | 2020 | |
| New World Medical,INC. | $78.18 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $76.99 | 2021 | |
| Coopervision INC. | $18.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noemi Lozano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.